Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Molecular diagnostic testing	$ 695.5	$ 748.2	$ 582.4
Pharmaceutical and clinical services	27.6	30.0	30.8
Total revenue	723.1	778.2	613.2
Costs and expenses:
Cost of molecular diagnostic testing	132.8	96.1	64.4
Cost of pharmaceutical and clinical services	14.6	13.1	15.3
Research and development expense	75.5	67.5	53.7
Selling, general, and administrative expense	366.0	327.1	251.8
Total costs and expenses	588.9	503.8	385.2
Operating income	134.2	274.4	228.0
other income (expense):
Interest income	0.4	5.4	5.5
Other	0.3	(2.0)	(0.2)
Total other income:	0.7	3.4	5.3
Income before income tax	134.9	277.8	233.3
Income tax provision	54.7	101.6	86.1
Net income	$ 80.2	$ 176.2	$ 147.2
Earnings per share:
Basic	$ 1.12	$ 2.33	$ 1.82
Diluted	$ 1.08	$ 2.25	$ 1.77
Weighted average shares outstanding:
Basic	71.3	75.7	80.9
Diluted	74.5	78.2	83.3